Renal Cancer News and Research

RSS

Study compares effectiveness of treatments for metastatic non-clear cell kidney cancers

A head-to-head comparison of two biologic therapies used to treat a subset of patients with advanced kidney cancers provides much-needed clarity on the preferred treatment for the first line of attack.

15 May 2015

Honokiol extract holds promise as adjunct treatment for bladder and kidney cancers

The botanical extract honokiol, a biologically active molecule isolated from the bark of Magnolia spp., holds promise as an adjunct treatment for aggressive bladder and kidney cancers, as reported in two new studies. New research on honokiol in bladder cancer was presented at the American Association for Cancer Research Annual Meeting 2015.

22 Apr 2015

Bionomics to present BNC105 trial results of metastatic renal cancer at Asian Oncology Summit

Bionomics Limited (ASX: BNO, OTCQX: BNOEF) today announced that it will present a poster with new data on the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the 7th Asian Oncology Summit being held from April 10-12, 2015 in Shanghai, China.

10 Apr 2015

Bionomics to present data from DisrupTOR-1 trial at ASCO Genitourinary Cancers Symposium

Bionomics Limited is to present important additional data from the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the ASCO Genitourinary Cancers Symposium in Orlando, Florida. The data will be presented by Dr. Sumanta Pal of the City of Hope Comprehensive Cancer Center in California in his poster presentation.

28 Feb 2015

Immune-suppressing protein may predict how patients respond to treatment

The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found.

27 Nov 2014

New study reveals link between aristolochic acid and kidney cancer

A new study on a large cohort of kidney cancer patients in Europe sheds light on the genetic architecture of the disease -- and reveals an apparent link between exposure to aristolochic acid and incidence of kidney cancer, particularly in Romania.

29 Oct 2014

Research to identify cancer-busting 'genetic partners' can personalize cancer treatment

Despite the revolutionary biotechnological advancements of the last few decades, an ideal anti-cancer treatment - one that's immediately lethal to cancer cells, harmless to healthy cells, and resistant to cancer's relapse - is still a dream.

4 Sep 2014

Marker identified for population of renal cancer cells with stem-cell-like features

Researchers have identified a population of clear cell renal cell carcinoma cells positive for the CTR2 marker that possess some stem-cell-like features and are able to induce an angiogenic response in vivo.

22 Jul 2014

Marker identified for population of renal cancer cells with stem-cell-like features

22 Jul 2014

Targeting CXCR4–CXCL12–CXCR7 axis combats mTOR inhibitor resistance in renal cancer

There is considerable crosstalk between the CXCR4–CXCL12–CXCR7 axis and the mammalian target of rapamycin pathway in human renal cell carcinoma, and targeting the axis may overcome drug resistance to mTOR inhibitors, researchers suggest.

22 Jul 2014

A personalized approach for patients with ccRCC-related mutations

In an analysis of small molecules called metabolites used by the body to make fuel in normal and cancerous cells in human kidney tissue, a research team from the Perelman School of Medicine at the University of Pennsylvania identified an enzyme key to applying the brakes on tumor growth.

21 Jul 2014

Protein may predict outcome of targeted mccRCC therapy

Levels of carbonic anhydrase 9 increase with the use of vascular endothelial growth factor-targeted therapy for metastatic clear-cell renal cancer, and high expression of this protein is associated with increased survival, show study results reported in European Urology.

3 Jul 2014

Reduced glomerular filtration rate is independent risk factor for renal and urothelial cancer

Researchers who investigated the level of kidney function and subsequent cancer risk in more than one million adults have found that reduced glomerular filtration rate (GFR) — a key measure of reduced kidney function and chronic kidney disease (CKD) — is an independent risk factor for renal and urothelial cancer but not other cancer types.

30 May 2014

Novel bioinformatics approach suggests antimicrobial drug may help in treating advanced kidney cancer

Developing and testing a new anti-cancer drug can cost billions of dollars and take many years of research.

6 May 2014

Study: Honokiol reduces proliferation of renal cell carcinoma

A new study shows that honokiol, a small molecule polyphenol extract derived from Magnolia officinalis bark, reduces proliferation of renal cell carcinoma.

9 Apr 2014

Vaccine targeting tumors could initiate immune response to fight cancer

Cincinnati Cancer Center (CCC) and UC Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune system, could initiate the immune response to fight cancer.

28 Feb 2014

Partial nephrectomy may offer younger renal cancer patients survival advantage

Partial nephrectomy may offer younger patients with localized renal cancer a distinct survival advantage compared with the complete removal of the kidney, US research suggests.

25 Feb 2014

Response of brain tumors from SRS can indicate necessity of follow-up treatments

The response of a patient with metastatic brain tumors to treatment with stereotactic radiosurgery in the first six-to-twelve weeks can indicate whether follow-up treatments and monitoring are necessary, according to research conducted at the University of North Carolina.

28 Jan 2014

Advanced melanoma treatments: an interview with Dr. James Larkin, Consultant Medical Oncologist, The Royal Marsden

Advanced melanoma affects around 2,000 people per year in the UK. Advanced melanoma describes a melanoma that has spread from its site of origin to other areas of the body.

22 Jan 2014

immatics biotechnologies closes €34 million Series D financing round

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced multi-peptide cancer vaccines that are active against cancer, today announced that it has closed a €34 million Series D financing round.

15 Oct 2013

Renal Cancer News and Research

Study compares effectiveness of treatments for metastatic non-clear cell kidney cancers

Honokiol extract holds promise as adjunct treatment for bladder and kidney cancers

Bionomics to present BNC105 trial results of metastatic renal cancer at Asian Oncology Summit

Bionomics to present data from DisrupTOR-1 trial at ASCO Genitourinary Cancers Symposium

Immune-suppressing protein may predict how patients respond to treatment

New study reveals link between aristolochic acid and kidney cancer

Research to identify cancer-busting 'genetic partners' can personalize cancer treatment

Marker identified for population of renal cancer cells with stem-cell-like features

Marker identified for population of renal cancer cells with stem-cell-like features

Targeting CXCR4–CXCL12–CXCR7 axis combats mTOR inhibitor resistance in renal cancer

A personalized approach for patients with ccRCC-related mutations

Protein may predict outcome of targeted mccRCC therapy

Reduced glomerular filtration rate is independent risk factor for renal and urothelial cancer

Novel bioinformatics approach suggests antimicrobial drug may help in treating advanced kidney cancer

Study: Honokiol reduces proliferation of renal cell carcinoma

Vaccine targeting tumors could initiate immune response to fight cancer

Partial nephrectomy may offer younger renal cancer patients survival advantage

Response of brain tumors from SRS can indicate necessity of follow-up treatments

Advanced melanoma treatments: an interview with Dr. James Larkin, Consultant Medical Oncologist, The Royal Marsden

immatics biotechnologies closes €34 million Series D financing round

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News